Bioisosteric phentolamine analogs as selective human α2- versus α1-adrenoceptor ligands

Supriya A. Bavadekar, Seoung Soo Hong, Sang II Lee, Duane Miller, Dennis R. Feller

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Phentolamine is known to act as a competitive, non-subtype-selective α-adrenoceptor antagonist. In an attempt to improve α2- versus α1-adrenoceptor selectivity and α2-adrenoceptor subtype-selectivity, two new chemical series of bioisosteric phentolamine analogs were prepared and evaluated. These compounds were evaluated for binding affinities on α1- (α1A-, α1B-, α1D-) and α2- (α2A-, α2B-, α2C-) adrenoceptor subtypes that had been stably expressed in human embryonic kidney and Chinese hamster ovary cell lines, respectively. Methylation of the phenolic hydroxy group and replacement of the 4-methyl group of phentolamine with varying lipophilic substituents yielded bioisosteric analogs selective for the α2- versus α1-adrenoceptors. Within the α2-adrenoceptors, these analogs bound with higher affinity at the α2A- and α2C-subtypes as compared to the α2B-subtype. In particular, the t-butyl analog was found to be the most selective, its binding at the α2C-adrenoceptor (Ki = 3.6 nM) being 37- to 173-fold higher than that at the α1-adrenoceptors, and around 2- and 19-fold higher than at the α2A- and α2B-adrenoceptors, respectively. Data from luciferase reporter gene assays confirmed the functional antagonist activities of selected compounds from the bioisosteric series on human α1A- and α2C-adrenoceptors. Thus, the results with these bioisosteric analogs of phentolamine provide a lead to the rational design of potent and selective α2-adrenoceptor ligands that may be useful in improving the therapeutic profile of this drug class for human disorders.

Original languageEnglish (US)
Pages (from-to)53-60
Number of pages8
JournalEuropean Journal of Pharmacology
Volume590
Issue number1-3
DOIs
StatePublished - Aug 20 2008

Fingerprint

Phentolamine
Adrenergic Receptors
Ligands
Cricetulus
Luciferases
Reporter Genes
Methylation
Ovary
Kidney
Cell Line

All Science Journal Classification (ASJC) codes

  • Pharmacology

Cite this

Bioisosteric phentolamine analogs as selective human α2- versus α1-adrenoceptor ligands. / Bavadekar, Supriya A.; Hong, Seoung Soo; Lee, Sang II; Miller, Duane; Feller, Dennis R.

In: European Journal of Pharmacology, Vol. 590, No. 1-3, 20.08.2008, p. 53-60.

Research output: Contribution to journalArticle

Bavadekar, Supriya A. ; Hong, Seoung Soo ; Lee, Sang II ; Miller, Duane ; Feller, Dennis R. / Bioisosteric phentolamine analogs as selective human α2- versus α1-adrenoceptor ligands. In: European Journal of Pharmacology. 2008 ; Vol. 590, No. 1-3. pp. 53-60.
@article{71f14bb4141c4f1eb50d020d0099197d,
title = "Bioisosteric phentolamine analogs as selective human α2- versus α1-adrenoceptor ligands",
abstract = "Phentolamine is known to act as a competitive, non-subtype-selective α-adrenoceptor antagonist. In an attempt to improve α2- versus α1-adrenoceptor selectivity and α2-adrenoceptor subtype-selectivity, two new chemical series of bioisosteric phentolamine analogs were prepared and evaluated. These compounds were evaluated for binding affinities on α1- (α1A-, α1B-, α1D-) and α2- (α2A-, α2B-, α2C-) adrenoceptor subtypes that had been stably expressed in human embryonic kidney and Chinese hamster ovary cell lines, respectively. Methylation of the phenolic hydroxy group and replacement of the 4-methyl group of phentolamine with varying lipophilic substituents yielded bioisosteric analogs selective for the α2- versus α1-adrenoceptors. Within the α2-adrenoceptors, these analogs bound with higher affinity at the α2A- and α2C-subtypes as compared to the α2B-subtype. In particular, the t-butyl analog was found to be the most selective, its binding at the α2C-adrenoceptor (Ki = 3.6 nM) being 37- to 173-fold higher than that at the α1-adrenoceptors, and around 2- and 19-fold higher than at the α2A- and α2B-adrenoceptors, respectively. Data from luciferase reporter gene assays confirmed the functional antagonist activities of selected compounds from the bioisosteric series on human α1A- and α2C-adrenoceptors. Thus, the results with these bioisosteric analogs of phentolamine provide a lead to the rational design of potent and selective α2-adrenoceptor ligands that may be useful in improving the therapeutic profile of this drug class for human disorders.",
author = "Bavadekar, {Supriya A.} and Hong, {Seoung Soo} and Lee, {Sang II} and Duane Miller and Feller, {Dennis R.}",
year = "2008",
month = "8",
day = "20",
doi = "10.1016/j.ejphar.2008.05.027",
language = "English (US)",
volume = "590",
pages = "53--60",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "1-3",

}

TY - JOUR

T1 - Bioisosteric phentolamine analogs as selective human α2- versus α1-adrenoceptor ligands

AU - Bavadekar, Supriya A.

AU - Hong, Seoung Soo

AU - Lee, Sang II

AU - Miller, Duane

AU - Feller, Dennis R.

PY - 2008/8/20

Y1 - 2008/8/20

N2 - Phentolamine is known to act as a competitive, non-subtype-selective α-adrenoceptor antagonist. In an attempt to improve α2- versus α1-adrenoceptor selectivity and α2-adrenoceptor subtype-selectivity, two new chemical series of bioisosteric phentolamine analogs were prepared and evaluated. These compounds were evaluated for binding affinities on α1- (α1A-, α1B-, α1D-) and α2- (α2A-, α2B-, α2C-) adrenoceptor subtypes that had been stably expressed in human embryonic kidney and Chinese hamster ovary cell lines, respectively. Methylation of the phenolic hydroxy group and replacement of the 4-methyl group of phentolamine with varying lipophilic substituents yielded bioisosteric analogs selective for the α2- versus α1-adrenoceptors. Within the α2-adrenoceptors, these analogs bound with higher affinity at the α2A- and α2C-subtypes as compared to the α2B-subtype. In particular, the t-butyl analog was found to be the most selective, its binding at the α2C-adrenoceptor (Ki = 3.6 nM) being 37- to 173-fold higher than that at the α1-adrenoceptors, and around 2- and 19-fold higher than at the α2A- and α2B-adrenoceptors, respectively. Data from luciferase reporter gene assays confirmed the functional antagonist activities of selected compounds from the bioisosteric series on human α1A- and α2C-adrenoceptors. Thus, the results with these bioisosteric analogs of phentolamine provide a lead to the rational design of potent and selective α2-adrenoceptor ligands that may be useful in improving the therapeutic profile of this drug class for human disorders.

AB - Phentolamine is known to act as a competitive, non-subtype-selective α-adrenoceptor antagonist. In an attempt to improve α2- versus α1-adrenoceptor selectivity and α2-adrenoceptor subtype-selectivity, two new chemical series of bioisosteric phentolamine analogs were prepared and evaluated. These compounds were evaluated for binding affinities on α1- (α1A-, α1B-, α1D-) and α2- (α2A-, α2B-, α2C-) adrenoceptor subtypes that had been stably expressed in human embryonic kidney and Chinese hamster ovary cell lines, respectively. Methylation of the phenolic hydroxy group and replacement of the 4-methyl group of phentolamine with varying lipophilic substituents yielded bioisosteric analogs selective for the α2- versus α1-adrenoceptors. Within the α2-adrenoceptors, these analogs bound with higher affinity at the α2A- and α2C-subtypes as compared to the α2B-subtype. In particular, the t-butyl analog was found to be the most selective, its binding at the α2C-adrenoceptor (Ki = 3.6 nM) being 37- to 173-fold higher than that at the α1-adrenoceptors, and around 2- and 19-fold higher than at the α2A- and α2B-adrenoceptors, respectively. Data from luciferase reporter gene assays confirmed the functional antagonist activities of selected compounds from the bioisosteric series on human α1A- and α2C-adrenoceptors. Thus, the results with these bioisosteric analogs of phentolamine provide a lead to the rational design of potent and selective α2-adrenoceptor ligands that may be useful in improving the therapeutic profile of this drug class for human disorders.

UR - http://www.scopus.com/inward/record.url?scp=48049118329&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=48049118329&partnerID=8YFLogxK

U2 - 10.1016/j.ejphar.2008.05.027

DO - 10.1016/j.ejphar.2008.05.027

M3 - Article

C2 - 18589415

AN - SCOPUS:48049118329

VL - 590

SP - 53

EP - 60

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 1-3

ER -